Patent classifications
C12Y201/01062
Cell line with METTL3 gene knocked out, its construction method and interference vector
A pig intestinal tract epithelium cell line with METTL3 gene knocked out and a construction method therefor. A gene interference vector for METTL3 form a pig is also provided.
TARGETING RNA VIRUSES USING INHIBITORS OF METTL3
Provided are methods for prophylaxis or therapy for an RNA virus infection. The methods involve modulating the Type I interferon pathway in RNA virus infected cells of an individual. The Type I interferon pathway is modulated by administering one or more agents to virus infected cells that inhibit the expression and/or function of METTL3 or inhibit expression and/or function of YTHDF1, YTHDF2 or YTHDF3.
Cell line with METTL3 gene knocked out, its construction method and interference vector
A pig intestinal tract epithelium cell line with METTL3 gene knocked out and a construction method therefor. A gene interference vector for METTL3 form a pig is also provided.
MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE
Methods and compositions for reducing drug resistance are described. Agents for decreasing m.sup.6A RNA methylation are described. Also described are compositions comprising the agents, methods of making the agents, and methods of using the agents to reduce drug resistance in a subject in need thereof, or to stimulate an immune response.
m6A mRNA MODIFICATION IN CANCER TREATMENT
Disclosed herein are methods of treating cancer by increasing mRNA m6A methylation level and/or decreasing mRNA m6A demethylation in cancer stem cells. The methods entail administering an effective amount of one or more therapeutic agents to the subject. The therapeutic agents include an agent that induces overexpression of METTL3, an agent that induces overexpression of METTL14, an agent that inhibits FTO, an agent that inhibits ALKBH5, and an agent that inhibits TLX. Also disclosed are pharmaceutical compositions for treating cancer, which compositions include one or more such therapeutic agents.
m6A mRNA MODIFICATION IN CANCER TREATMENT
Disclosed herein are methods of treating cancer by increasing mRNA m6A methylation level and/or decreasing mRNA m6A demethylation in cancer stem cells. The methods entail administering an effective amount of one or more therapeutic agents to the subject. The therapeutic agents include an agent that induces overexpression of METTL3, an agent that induces overexpression of METTL14, an agent that inhibits FTO, an agent that inhibits ALKBH5, and an agent that inhibits TLX. Also disclosed are pharmaceutical compositions for treating cancer, which compositions include one or more such therapeutic agents.